KRMD earnings analysis
What we found in KRMD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
KORU Medical Systems reported strong revenue growth of 22.1% in Q1 2026, reaching $11.8 million driven by domestic and international core businesses as well as significant increases in pharma services and clinical trials. Despite a decrease in gross margin to 61.5%, the net loss narrowed to $807,078 compared to a loss of $1.2 million in the prior year, indicating improved operational efficiency.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Total revenue increased by 22.1% to $11.8 million, up from $9.6 million in Q1 2025.
- Improved Net Loss
- Net loss decreased by 30.8% to $807,078 versus a loss of $1.2 million in the prior year.
- Growth in Pharma Services
- Pharma services and clinical trials revenue surged 166.0%, contributing $740,711 compared to $278,449 last year.
- Increased Domestic Core Revenue
- Domestic core revenue rose 11.7% to $7.7 million, from $6.9 million in Q1 2025.
- Balance Sheet Liquidity Maintained
- Cash on hand was $8.8 million, providing sufficient liquidity for operational needs.
- Better Operational Cash Flows
- Net cash from operating activities improved to $14,663 compared to $(237,467) in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Decreasing Gross Margin
- Gross margin declined to 61.5% from 62.8% due to rising production costs and tariffs.
- Potential Economic Headwinds
- Management noted risks related to inflation, geopolitical conflicts, and cost recovery that may impact future performance.
- Dependence on Key Personnel
- The risk of losing key personnel remains a concern and could affect strategic plans and operational execution.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 61.5%
- Segment
- Domestic Core: $7.7 million
- Segment
- International Core: $3.3 million
- Segment
- Pharma Services: $740,711
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · March 12, 2026
- KORU Medical’s 10-K describes a clear strategy to deepen leadership in the large-volume subcutaneous infusion (SCIg) market via its FREEDOM System while expanding into novel subcutaneous therapies and pharma services.…
- 10-Q · August 6, 2025
- KORU Medical reported Q2 net revenues of $10,194,800, up $1,764,711 (20.9%) versus Q2 2024 and up $559,725 (5.8%) sequentially. Gross margin was 63.5% (6,475,769 gross profit) and operating loss narrowed to $312,655…
- 10-Q · May 1, 2024
- KORU Medical reported Q1 revenue of $8,197,798, up from $7,392,605 a year earlier, with gross profit of $5,103,298 and a gross margin ~62.3%. The company still recorded a GAAP net loss of $1,935,958 (loss per share…
- 10-Q · May 4, 2023
- KORU Medical reported Q1 net sales of $7,392,605, up $1,148,275 (18.4%) versus $6,244,330 a year ago, with gross profit rising to $4,147,035 but gross margin compressing to 56.1%. The company narrowed net loss to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KRMD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever